PaniaguaR., AmatoD., VoneshE., Correa-RotterR., RamosA., MoranJ.Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.J Am Soc Nephrol2002; 13: 1307–20.
2.
LoW.K., HoY.W., LiC.S., WongK.S., ChanT.M., YuA.W.Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study.Kidney Int2003, 64: 649–56.
3.
Peritoneal Dialysis Adequacy Work Group.Clinical practice guidelines for peritoneal dialysis adequacy.Am J Kidney Dis2006; 48(Suppl 1): S98–129.
4.
RigbyR.J., HawleyC.M.Sclerosing peritonitis: the experience in Australia.Nephrol Dial Transplant1998; 13: 154–9.
5.
SummersA.M., ClancyM.J., SyedF., HarwoodN., BrenchleyP.E., AugustineT.Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.Kidney Int2005; 68: 2381–8.
6.
WannerC., KraneV., MarzW., OlschewskiM., MannJ.F., RufG.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [Published erratum appears in N Engl J Med 2005; 353: 1640].N Engl J Med2005; 353: 328–48.
